1.29
-0.01(-0.77%)
Currency In USD
| Previous Close | 1.3 |
| Open | 1.29 |
| Day High | 1.3 |
| Day Low | 1.27 |
| 52-Week High | 2.04 |
| 52-Week Low | 1.11 |
| Volume | 2.28M |
| Average Volume | 2.56M |
| Market Cap | 990.33M |
| PE | -5.37 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.37 |
| Moving Average 200 Days | 1.4 |
| Change | -0.01 |
If you invested $1000 in OPKO Health, Inc. (OPK) 10 years ago, it would be worth $127.34 as of December 28, 2025 at a share price of $1.29. Whereas If you bought $1000 worth of OPKO Health, Inc. (OPK) shares 5 years ago, it would be worth $329.08 as of December 28, 2025 at a share price of $1.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 19, 2025 9:05 PM GMT
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
GlobeNewswire Inc.
Oct 29, 2025 12:00 PM GMT
Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OP
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX